login
quiescence.eu

Harnessing innovation in nuclear science, technology and radiation protection

Closed

Status as published by the data source.

Sign in to bookmark this

Expected Outcome:Project results are expected to contribute to some of the following expected outcomes:

• Bring a breakthrough innovation in radiation protection and emergency preparedness to improve protection against ionising radiation, bringing benefits to society using cross-cutting technologies like digitalisation, modelling or simulation, and artificial intelligence where appropriate.
• Address safety aspects of alternative applications of nuclear energy (e.g. hydrogen production, process heat for energy-intensive industries, district heating and desalinisation), allowing some Member States to contribute to the energy transition according to and respecting the EU technology neutrality principle and thus increase Member State and EU security of supply.
• Develop new nuclear techniques or optimise existing ones in the medical field, addressing in particular safety and radiation protection aspects.
• Support the development of European production of stable isotopes used in novel nuclear medicine therapies.
• Bring innovation in communication about nuclear applications and their risks to ensure informed decisions by stakeholders, civil society and decision-makers. Scope:This action aims to bring innovation, including via cross-fertilisation with other scientific and technical sectors, to radiation protection. This complements the PIANOFORTE European partnership in medical applications and emergency preparedness, alternative applications of nuclear energy, and risk communication with civil society and decision-makers.
In terms of radiation protection and emergency preparedness, the PIANOFORTE partnership will be the main driving force for research for the coming 5 years, consolidating an EU-wide research and innovation community. The purpose of this action is to complement the PIANOFORTE partnership by fostering frontier research and testing novel ideas that can bring about a breakthrough innovation in the field. The proposals should complement, without duplicating, the research challenges addressed in the PIANOFORTE research roadmap.
In the context of the energy transition and complementing Horizon Europe’s objectives, nuclear energy and innovative nuclear technology applications can provide some Member States with solutions to support climate change mitigation. Nuclear technologies could provide solutions that enable energy-intensive industries to develop and reduce their environmental footprint while remaining competitive. Nuclear has the potential to supply heat to homes, businesses and industrial processes, and produce hydrogen and synthetic fuels or non-electric commodities such as purified water or fertilisers. Some non-electric applications for nuclear energy have been demonstrated and implemented by industry, but their full potential still needs to be demonstrated. The Euratom-funded action should address the safety challenges related to developing and implementing non-electric applications for nuclear energy.
Concerning human health, there are many technologies in various fields of medical applications of ionising radiation. These include targeted radionuclide therapy, targeted therapies based on ion or proton therapy, new technologies for interventional imaging procedures and molecular imaging approaches, and the development of vaccines using irradiation techniques. The rapidly developing medical radiation technologies are becoming more complex and increasingly rely on automation, computerised decision support and AI-based systems. The Euratom-funded action should address the development of new quality assured nuclear techniques or optimisation of existing ones in the medical field. This includes data processing methodologies using artificial intelligence, optimisation of the medical use of ionising radiation and corresponding optimisation of radiation protection.
Each year, patients in Europe benefit from nuclear medicine in diagnosing and treating illnesses such as cancer, cardiovascular or neurological disorders. The EU supply of novel radiopharmaceuticals for cancer therapy is at risk due to the growing uncertainties over imports of enriched stable isotopes from Russia. Ensuring European know-how and the EU’s strategic capabilities in this field is essential for the decades to come.
When communicating about nuclear applications and their risks, proposals are expected to bring about and test novel ideas for risk communication to ensure informed decisions by stakeholders, civil society and decision-makers.

Status
Closed
Deadline
(time not stated)
Opens
Published
Total budget
€7,000,000
Grant range
€3,500,000 – €3,500,000
Country
European Union (EU-wide)
Programme
Euratom Research and Training Programme (EURATOM)
Official page
Open at the source portal

Other calls under Euratom Research and Training Programme (EURATOM)

All calls under this programme

Similar opportunities

Where this came from

Source document
https://ec.europa.eu/info/funding-tenders/opportunities/data/topicDetails/horizon-euratom-2023-nrt-01-10.json
Document fingerprint
bbbf27fce0b8ae4a (SHA-256, first 16 hex characters)
Retrieved
First recorded here

What has changed

Data source

© European Union, 2026. Source: EU Funding & Tenders Portal. Reused under Commission Decision 2011/833/EU — CC BY 4.0.

Retrieved from the source on .

The source last updated this document on Tue, 01 Jul 2025 07:57:18 GMT.

Personal data of natural persons has been dissociated by quiescence.eu.

This service is not affiliated with, sponsored or endorsed by the data publishers.